A regulatory role for β-adrenergic receptors regarding the resolvin D1 (RvD1) pathway in the diabetic retina.
Diabetic retinopathy is a visually debilitating disease with limited treatment options available. Compound 49b, a β-adrenergic receptor agonist, has been demonstrated to effectively reduce disease pathogenesis associated with diabetic retinopathy. While the exact mechanisms are not fully understood,...
Main Authors: | Haoshen Shi, Thomas W Carion, Youde Jiang, Adam Chahine, Jena J Steinle, Elizabeth A Berger |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5667888?pdf=render |
Similar Items
-
Análisis transcripcional de la región genética RvD1 de Mycobacterium bovis
by: Víctor Manuel Tibatá R., et al.
Published: (2004-07-01) -
Interplay between Intravitreal RvD1 and Local Endogenous Sirtuin-1 in the Protection from Endotoxin-Induced Uveitis in Rats
by: S. Rossi, et al.
Published: (2015-01-01) -
A Synthetic Resolvin Analogue (Benzo-Rvd1) Attenuates Vascular Smooth Muscle Cell Migration and Neointimal Hyperplasia
by: Evan C. Werlin, et al.
Published: (2020-01-01) -
RvD1 Attenuated Susceptibility to Ischemic AKI in Diabetes by Downregulating Nuclear Factor-κ B Signal and Inhibiting Apoptosis
by: Zheng Li, et al.
Published: (2021-07-01) -
Inhibition of lung cancer growth and metastasis by DHA and its metabolite, RvD1, through miR-138-5p/FOXC1 pathway
by: Xiaoming Bai, et al.
Published: (2019-11-01)